0QK8 Stock Chart & Stats
$23.17
$0.74(3.30%)
At close: 4:00 PM EDT
$23.17
$0.74(3.30%)
Day’s Range― - ―
52-Week Range$15.74 - $29.91
Previous CloseN/A
Volume6.28K
Average Volume (3M)4.90K
Market Cap
$13.59B
Enterprise Value$17.72K
Total Cash (Recent Filing)$2.15B
Total Debt (Recent Filing)$9.67B
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Oct 29, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield0.75%
Share Statistics
EPS (TTM)-2.04
Shares Outstanding516,996,000
10 Day Avg. Volume3,277
30 Day Avg. Volume4,898
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$25.90Price Target Upside11.78% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)2.04
Revenue Forecast (FY)$11.61B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Installed-base DemandBaxter’s recurring-use consumables and therapy-linked products create repeat demand from hospitals and dialysis providers. Device placements can also support follow-on sales of compatible sets and accessories, providing durable customer relationships and revenue visibility.
Broad-based Revenue GrowthGrowth across all segments and geographies indicates improving underlying demand rather than reliance on one isolated business. Management’s raised 2026 sales outlook further supports the view that Baxter’s portfolio is gaining traction over the next several quarters.
Positive Cash Generation And Operational ImprovementPositive operating and free cash flow provide resources to fund operations, debt reduction and product investment despite accounting losses. Baxter GPS initiatives focused on efficiency, working capital and simplification may improve cash conversion and margins over time.
Bears Say
Persistent UnprofitabilityNegative EBIT and net income show that Baxter’s revenue base is not currently translating into durable shareholder returns. Compressed EBITDA also suggests weaker operating leverage or higher costs, limiting the company’s ability to self-fund growth and reduce debt.
Elevated Leverage And Reduced Financial FlexibilityAlthough leverage has improved from 2022, Baxter remains meaningfully geared while returns are negative. Debt service and covenant management can constrain investment, dividends and resilience if operating recovery is slower than expected.
Infusion Disruption And Supply-chain PressureThe Novum IQ hold can weaken infusion-system sales, trigger customer returns and create uncertainty around Baxter’s platform transition. Ongoing injectable constraints and contract-manufacturer issues may also limit volume, customer confidence and margin recovery.
Baxter International News
0QK8 FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest share price was $15.74 and its highest was $29.91 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is $13.59B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Jul 30, 2026. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.367 by $0.193.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 0.75%. See more information on Baxter International dividends here
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 0.52.
How many shares outstanding does Baxter International have?
Baxter International has 516,996,000 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of $0.56 in its last earnings report, beating expectations of $0.367. Following the earnings report the stock price went up 6.577%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in GB:0QK8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$25.90 (11.78% Upside)
$25.90 (11.78% Upside)
Blogger Sentiment
Bullish
GB:0QK8 Sentiment 71%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.47%
12-Months-Change
Fundamentals
Return on Equity
0.75%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Baxter International
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
0QK8 Company Deck
0QK8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a mostly positive picture: revenue growth was broad-based with Q2 organic sales up 5%, management raised full-year sales and EPS guidance, free cash flow and balance sheet metrics improved, and several product and operational initiatives showed traction (Baxter GPS, PeerVue, Connex 360, Dynamo). However, meaningful near-term headwinds remain — margin pressure from higher-cost inventory and tariffs, ongoing supply constraints (notably in injectables), and the disruption around the Novum IQ LVP platform. The tariff refund was a helpful one-time boost but is nonrecurring. On balance, the company demonstrated tangible operational progress and raised guidance while acknowledging discrete challenges that are being managed.View all GB:0QK8 earnings summaries0QK8 Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
0QK8 Stock 12 Month Forecast
Average Price Target
$25.90
▲(11.78% Upside)